Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Rachel L. McMinn
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 131
- Beta
- 1.96
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 6.05
Financials
Revenue
$0.00-100.0%Net Income
$-34.49MEBITDA
$-32.11MFree Cash Flow
$-24.11MEPS (diluted)
$-1.53Shares Outstanding (diluted)
22.55M+27.5%Operating Expenses
$36.67MCash & Debt
$225.39MRevenue by Segment (annual)
$925.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-90.35M | $-4.24 |
| 2024 | $925.0K | $-75.14M | $-4.28 |
| 2023 | $0.00 | $-36.32M | $-2.83 |
| 2022 | $0.00 | $-55.19M | $-4.30 |
| 2021 | $0.00 | $-50.52M | $-0.92 |
| 2020 | $0.00 | $-33.28M | $-0.64 |
| 2019 | $0.00 | $-69.44M | $-2.57 |
| 2018 | $25.00M | $-31.59M | $-1.34 |
| 2017 | $0.00 | $-50.18M | $-2.14 |
| 2016 | $0.00 | $-37.00M | $-1.96 |
| 2015 | $0.00 | $-21.86M | $-1.73 |
| 2014 | $0.00 | $-23.82M | $-2.75 |
| 2013 | $0.00 | $-8.73M | $-0.87 |
| 2012 | $0.00 | $-7.71M | $-0.77 |
Valuation
NGNEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·18h ago·Neutral
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company's common stock to five new employees (…
View source ↗ - Newsbusinesswire.com·28d ago·Neutral
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, Sept…
View source ↗ - Newsbusinesswire.com·31d ago·Neutral
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of the Company's common stock to two new employees (…
View source ↗ - Newsbusinesswire.com·56d ago·Positive
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2026 financial results and highlighted recent corporate updates. “The second quarter and recent months marked important progress across our NGN-401 program, highlighted by positive long-
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-1.33 per share
Typical surprise +4.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-1.53 vs $-1.42miss
- Tue, May 12$-1.39 vs $-1.30miss
- Tue, Mar 24$-1.12 vs $-1.24beat
- Fri, Nov 14$-0.99 vs $-1.26beat
- Mon, Aug 11$-1.05 vs $-1.15beat
- Fri, May 9$-1.08 vs $-1.05miss
Estimates and results for NGNE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NGNE officers and directors.
- Bought
- $2.7m
- Sold
- $1.3m
6 trades
19 trades
- Cvijic Christine Mikailsold
- Cvijic Christine Mikailsold
- Cvijic Christine Mikailsold
- Cvijic Christine Mikailsold
- Cvijic Christine Mikailsold
- Cvijic Christine Mikailsold
- Cvijic Christine Mikailsold
- Cvijic Christine Mikailsold
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NGNE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.